XML 29 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net income (loss) $ (3,903) $ 1,502 $ 1,675
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:      
Depreciation, amortization and accretion 1,738 1,754 1,707
Goodwill Impairment 4,958 0 0
(Gains) losses on retirement of long-term obligations [1] 0 0 28
Amortization of deferred financing costs and other non-cash interest 32 29 17
Stock-based compensation expense, net 131 157 156
Asset write-down charges 148 33 34
Deferred income tax (benefit) provision 4 8 3
Restructuring Reserve, Settled without Cash 12 7 0
Other non-cash adjustments, net 23 7 5
Changes in assets and liabilities, excluding the effects of acquisitions:      
Increase (decrease) in accrued interest 25 36 0
Increase (decrease) in accounts payable (22) (14) (5)
Increase (decrease) in other liabilities (91) (265) (281)
Decrease (increase) in receivables 6 115 (49)
Decrease (increase) in other assets (118) (243) (412)
Net cash provided by (used for) operating activities 2,943 3,126 2,878
Cash flows from investing activities:      
Payments to Acquire Productive Assets (1,222) (1,424) (1,310)
Payments for acquisitions, net of cash acquired (8) (96) (35)
Other investing activities, net 10 1 (7)
Net cash provided by (used for) investing activities (1,220) (1,519) (1,352)
Cash flows from financing activities:      
Proceeds from issuance of long-term debt 1,244 3,843 748
Principal payments on debt and other long-term obligations (99) (79) (74)
Purchases and redemptions of long-term debt (750) (750) (1,274)
Borrowings under revolving credit facility 0 3,613 3,495
Payments under revolving credit facility (670) (4,248) (2,855)
Net issuances (repayments) under commercial paper program 1,341 (1,241) 976
Payments for financing costs (12) (39) (14)
Purchases of common stock (33) (30) (65)
Dividends/distributions paid on common stock (2,729) (2,723) (2,602)
Net cash provided by (used for) financing activities (1,708) (1,654) (1,665)
Cash, Cash Equivalents, and Restricted Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 15 (47) (139)
Cash, Cash Equivalents, and Restricted Cash and Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (1) 1 0
Cash, Cash Equivalents and Restricted Cash and Cash Equivalents - Beginning of Period 281 327 466
Cash, Cash Equivalents and Restricted Cash and Cash Equivalents - End of Period $ 295 $ 281 $ 327
[1] Inclusive of the write-off of the respective deferred financing costs